Evidence map›Paper›PMID 41984624›Full record

ArticleJMIR AI2026

Augmenting Large Language Model With Prompt Engineering and Supervised Fine-Tuning in Non-Small Cell Lung Cancer Tumor-Node-Metastasis Staging: Framework Development and Validation.

Ruonan Jin, Chao Ling, Yixuan Hou, Yuhan Sun, Ning Li, Jiefei Han, Jin Sheng, Qizhao Wang, Yuepeng Liu, Shen Zheng and 4 more

Abstract read
In one paragraph

Article in JMIR AI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ruonan Jin *Liangyihui Network Technology Co, Ltd, 9/F, Tower T2, Jinheshangcheng, 140 Tianlin Road, Xuhui District, Shanghai, Shanghai, 200233, China, 86 13636599645.ORCID 0009-0003-5567-5398
Chao Ling *Liangyihui Network Technology Co, Ltd, 9/F, Tower T2, Jinheshangcheng, 140 Tianlin Road, Xuhui District, Shanghai, Shanghai, 200233, China, 86 13636599645.ORCID 0009-0003-3578-8862
Yixuan HouSchool of Medicine, Tongji University, Shanghai, Shanghai, China.ORCID 0009-0000-3488-4121
Yuhan SunLiangyihui Network Technology Co, Ltd, 9/F, Tower T2, Jinheshangcheng, 140 Tianlin Road, Xuhui District, Shanghai, Shanghai, 200233, China, 86 13636599645.ORCID 0009-0008-0044-5532
Ning LiDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.ORCID 0009-0005-6640-6585
Jiefei HanDepartment of Neuro-oncology, Neurosurgery Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China.ORCID 0000-0003-4686-2530
Jin ShengDepartment of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.ORCID 0000-0002-1090-6426
Qizhao WangLiangyihui Network Technology Co, Ltd, 9/F, Tower T2, Jinheshangcheng, 140 Tianlin Road, Xuhui District, Shanghai, Shanghai, 200233, China, 86 13636599645.ORCID 0009-0001-3297-434X
Yuepeng LiuLiangyihui Network Technology Co, Ltd, 9/F, Tower T2, Jinheshangcheng, 140 Tianlin Road, Xuhui District, Shanghai, Shanghai, 200233, China, 86 13636599645.ORCID 0009-0003-5932-0826
Shen ZhengLiangyihui Network Technology Co, Ltd, 9/F, Tower T2, Jinheshangcheng, 140 Tianlin Road, Xuhui District, Shanghai, Shanghai, 200233, China, 86 13636599645.ORCID 0009-0000-0822-2976
Xingyu RenNoDesk AI Technology Co.,Ltd, Hangzhou, Zhejiang, China.ORCID 0009-0004-3526-3035
Chiyu ChenZhipu AI Technology Co, Ltd, Beijing, Beijing, China.ORCID 0009-0009-3767-7158
Jue WangLiangyihui Network Technology Co, Ltd, 9/F, Tower T2, Jinheshangcheng, 140 Tianlin Road, Xuhui District, Shanghai, Shanghai, 200233, China, 86 13636599645.ORCID 0009-0006-3342-5736
Cheng LiLiangyihui Network Technology Co, Ltd, 9/F, Tower T2, Jinheshangcheng, 140 Tianlin Road, Xuhui District, Shanghai, Shanghai, 200233, China, 86 13636599645.ORCID 0009-0004-9681-7652

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Accurate tumor node metastasis (TNM) staging is fundamental for treatment planning and prognosis in non-small cell lung cancer (NSCLC). However, its complexity poses significant challenges. Traditional rule-based natural language processing methods are constrained by their reliance on manually crafted rules and are susceptible to inconsistencies in clinical reporting. Objective: This study aimed to develop and validate a robust, accurate, and operationally efficient artificial intelligence framework for the TNM staging of NSCLC by strategically enhancing a large language model, GLM-4-Air (general language model), through advanced prompt engineering and supervised fine-tuning (SFT). Methods: We constructed a curated dataset of 492 deidentified real-world medical imaging reports, with TNM staging annotations rigorously validated by senior physicians according to the AJCC (American Joint Committee on Cancer) 8th edition guidelines. The GLM-4-Air model was systematically optimized via a multi-phase process: iterative prompt engineering incorporating chain-of-thought reasoning and domain knowledge injection for all staging tasks, followed by parameter-efficient SFT using low-rank adaptation for the reasoning-intensive primary tumor characteristics (T) and regional lymph node involvement (N) staging tasks. The final hybrid model was evaluated on a completely held-out test set (black-box) and benchmarked against GPT-4o using standard metrics, statistical tests, and a clinical impact analysis of staging errors. Results: The optimized hybrid GLM-4-Air model demonstrated reliable performance. It achieved higher staging accuracies on the black-box test set: 92% (95% CI 0.850-0.959) for T, 86% (95% CI 0.779-0.915) for N, 92% (95% CI 0.850-0.959) for distant metastasis status (M), and 90% for overall clinical staging; by comparison, GPT-4o attained 87% (95% CI 0.790-0.922), 70% (95% CI 0.604-0.781), 78% (95% CI 0.689-0.850), and 80%, respectively. The model's robustness was further evidenced by its macro-average F1-scores of 0.914 (T), 0.815 (N), and 0.831 (M), consistently surpassing those of GPT-4o (0.836, 0.620, and 0.698). Analysis of confusion matrices confirmed the model's proficiency in identifying critical staging features while effectively minimizing false negatives. Crucially, the clinical impact assessment showed a substantial reduction in severe category I errors, which are defined as misclassifications that could significantly influence subsequent clinical decisions. Our model committed 0 category I errors in M staging and fewer category I errors in T and N staging. Furthermore, the framework demonstrated practical deployability, achieving efficient inference on consumer-grade hardware (eg, 4 RTX 4090 GPUs) with latencies suitable and acceptable for clinical workflows. Conclusions: The proposed hybrid framework, integrating structured prompt engineering and applying SFT to reasoning-heavy tasks (T/N), enables the GLM-4-Air model to serve as a highly accurate, clinically reliable, and cost-efficient solution for automated NSCLC TNM staging. This work demonstrates the efficacy and potential of a domain-optimized smaller model compared with an off-the-shelf generalist model, holding promise for enhancing diagnostic standardization in resource-aware health care environments.

Indexed as

AIartificial intelligenceclinical decision supportdiagnostic standardizationGLM-32BGPT-4ograssroots health care improvementlarge language modelsnon-small cell lung cancerprompt engineeringsupervised fine tuningTNM staging

Identifiers

PMID41984624
PMCPMC13082344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.